Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
Total Valuation
Atea Pharmaceuticals has a market cap or net worth of $482.02M. The enterprise value is $377.80M.
Market Cap$482.02M
Enterprise Value$377.80M
Share Statistics
Atea Pharmaceuticals has 79,672,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding79,672,080
Owned by Insiders11.25%
Owned by Institutions21.72%
Financial Efficiency
Atea Pharmaceuticals’s return on equity (ROE) is -0.57 and return on invested capital (ROIC) is -63.02%.
Return on Equity (ROE)-0.57
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-63.02%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee0.00
Profits Per Employee-2.83M
Employee Count56
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Atea Pharmaceuticals is ―. Atea Pharmaceuticals’s PEG ratio is 0.61.
PE Ratio―
PS Ratio0.00
PB Ratio1.06
Price to Fair Value1.06
Price to FCF-2.20
Price to Operating Cash Flow-3.58
PEG Ratio0.61
Income Statement
In the last 12 months, Atea Pharmaceuticals had revenue of 0.00 and earned -158.35M in profits. Earnings per share was -1.94.
Revenue0.00
Gross Profit-416.00K
Operating Income-180.89M
Pretax Income-164.51M
Net Income-158.35M
EBITDA-180.89M
Earnings Per Share (EPS)-1.94
Cash Flow
In the last 12 months, operating cash flow was -132.03M and capital expenditures 0.00, giving a free cash flow of -132.03M billion.
Operating Cash Flow-132.03M
Free Cash Flow-132.03M
Free Cash Flow per Share-1.66
Dividends & Yields
Atea Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change93.29%
50-Day Moving Average4.38
200-Day Moving Average3.56
Relative Strength Index (RSI)80.13
Average Volume (3m)586.30K
Important Dates
Atea Pharmaceuticals upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateMar 5, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Atea Pharmaceuticals as a current ratio of 7.82, with Debt / Equity ratio of 0.31%
Current Ratio7.82
Quick Ratio7.82
Debt to Market Cap<0.01
Net Debt to EBITDA0.52
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Atea Pharmaceuticals has paid -6.16M in taxes.
Income Tax-6.16M
Effective Tax Rate0.04
Enterprise Valuation
Atea Pharmaceuticals EV to EBITDA ratio is -1.08, with an EV/FCF ratio of -1.49.
EV to Sales0.00
EV to EBITDA-1.08
EV to Free Cash Flow-1.49
EV to Operating Cash Flow-1.49
Balance Sheet
Atea Pharmaceuticals has $301.83M in cash and marketable securities with $843.00K in debt, giving a net cash position of $300.99M billion.
Cash & Marketable Securities$301.83M
Total Debt$843.00K
Net Cash$300.99M
Net Cash Per Share$3.78
Tangible Book Value Per Share$3.38
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Atea Pharmaceuticals is $7.10, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.10
Price Target Upside16.39% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast14.33%